John Baer
YOU?
Author Swipe
View article: Supplementary Table 3 from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer
Supplementary Table 3 from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer Open
Supplementary Table 3
View article: Supplementary Figures from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer
Supplementary Figures from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer Open
Supplemental Figures and Legends
View article: Supplementary Table 2 from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer
Supplementary Table 2 from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer Open
Supplementary Table 2
View article: Supplementary Table 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Supplementary Table 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Supplementary Table 1. Antibodies used in flow cytometry.
View article: Data from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Data from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Purpose:Targeting tumor-associated macrophages through C–C chemokine receptor type 2 (CCR) in pancreatic ductal adenocarcinoma (PDAC) improves the efficacy of chemotherapy and restores T-cell immunity in preclinical models.Patients and Met…
View article: Supplementary Table 2 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Supplementary Table 2 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Supplementary Table 2. Representativeness of study participants.
View article: Supplementary Figure 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Supplementary Figure 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Supplementary Figure 1. Data supporting correlative analyses.
View article: Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Purpose: Targeting tumor-associated macrophages through C–C chemokine receptor type 2 (CCR) in pancreatic ductal adenocarcinoma (PDAC) improves the efficacy of chemotherapy and restores T-cell immunity in preclinical models. Patients and M…
View article: <i>Arabidopsis</i> uses a molecular grounding mechanism and a biophysical circuit breaker to limit floral abscission signaling
<i>Arabidopsis</i> uses a molecular grounding mechanism and a biophysical circuit breaker to limit floral abscission signaling Open
Abscission is the programmed separation of plant organs. It is widespread in the plant kingdom with important functions in development and environmental response. In Arabidopsis, abscission of floral organs (sepals, petals, and stamens) is…
View article: Fig. S10 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S10 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S10 shows GSEA and heat map of CAF populations and orthotropic growth of EO771 cells +/-senCAF.
View article: Fig. S8 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S8 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S8 shows gating strategies for immune cell populations.
View article: Fig. S8 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S8 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S8 shows gating strategies for immune cell populations.
View article: Fig. S7 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S7 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S7 shows changes in immune populations in INK and ABT737 treated mice and impact of T cell depletion on the INK model.
View article: Fig. S6 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S6 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S6 shows scRNA-Seq analysis of INK and ABT737 treated animals focusing on CAFs and immune populations.
View article: Fig. S6 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S6 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S6 shows scRNA-Seq analysis of INK and ABT737 treated animals focusing on CAFs and immune populations.
View article: Supplementary Table 1 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
Supplementary Table 1 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer Open
Supplementary Table 1
View article: Supplementary Figures from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
Supplementary Figures from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer Open
Supplemental Figures and Legends
View article: Supplementary Table 1 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
Supplementary Table 1 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer Open
Supplementary Table 1
View article: Fig. S4 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S4 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S4 shows CAF gating strategy and PCA analysis or sorted CAF populations following bulk RNA-Seq.
View article: Data from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
Data from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer Open
Intratumoral T-cell dysfunction is a hallmark of pancreatic tumors, and efforts to improve dendritic cell (DC)-mediated T-cell activation may be critical in treating these immune therapy unresponsive tumors. Recent evidence indicates that …
View article: Fig. S3 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S3 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S3 shows mIHC and shows vCAF and image analysis masking strategy.
View article: Data from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Data from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
The tumor microenvironment (TME) profoundly influences tumorigenesis, with gene expression in the breast TME capable of predicting clinical outcomes. The TME is complex and includes distinct cancer-associated fibroblast (CAF) subtypes whos…
View article: Data from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Data from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
The tumor microenvironment (TME) profoundly influences tumorigenesis, with gene expression in the breast TME capable of predicting clinical outcomes. The TME is complex and includes distinct cancer-associated fibroblast (CAF) subtypes whos…
View article: Fig. S1 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S1 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S1 shows scRNA-Seq analyses of ER+, HER2+, and TNBC focusing on CAFs.
View article: Fig. S4 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S4 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S4 shows CAF gating strategy and PCA analysis or sorted CAF populations following bulk RNA-Seq.
View article: Fig. S7 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S7 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S7 shows changes in immune populations in INK and ABT737 treated mice and impact of T cell depletion on the INK model.
View article: Fig. S5 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S5 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S5 shows p16 IHC and CAF quantification after AP or ABT737 treatment.
View article: Supplementary Table 3 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
Supplementary Table 3 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer Open
Supplementary Table 3
View article: Fig. S2 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S2 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S2 shows scRNA-Seq from MMTV-PyMT mice focusing on CAFs and SA-BGal staining.
View article: Fig. S1 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Fig. S1 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression Open
Supplementary figure S1 shows scRNA-Seq analyses of ER+, HER2+, and TNBC focusing on CAFs.